This article builds on key discussions from a recent biostatistics and biopharma innovation symposium, exploring how science, data, and capital are reshaping the industry. It highlights the major forces defining biopharma in 2025 — including innovation trends, funding dynamics, regulatory shifts, and the growing competition between the U.S. and China.
